Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iSpecimen (ISPC) Gains from Sales and Divestitures (2024 - 2025)

iSpecimen has reported Gains from Sales and Divestitures over the past 2 years, most recently at $400.0 for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $400.0 for Q4 2025, down 77.78% from a year ago — trailing twelve months through Dec 2025 was $400.0 (down 77.78% YoY), and the annual figure for FY2025 was $400.0, down 77.78%.
  • Gains from Sales and Divestitures for Q4 2025 was $400.0 at iSpecimen, up from $382.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for ISPC hit a ceiling of $1800.0 in Q4 2024 and a floor of $152.0 in Q1 2025.